Company Description
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications.
The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 29, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | James Windsor |
Contact Details
Address: 12407 N. Mopac Expy., Suite 250 #390 Austin, Texas 78758 United States | |
| Phone | 737 802 1989 |
| Website | aileronrx.com |
Stock Details
| Ticker Symbol | ALRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420565 |
| CUSIP Number | 00887A105 |
| ISIN Number | US00887A2042 |
| Employer ID | 13-4196017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James Brian Windsor Ph.D. | Chief Executive Officer, President and Director |
| Timothy M. Cunningham CPA, M.B.A. | Interim Chief Financial Officer and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jul 26, 2024 | 8-K | Current Report |
| Jul 26, 2024 | 424B5 | Filing |
| Jul 26, 2024 | 424B5 | Filing |
| Jul 9, 2024 | ARS | Filing |
| Jul 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 9, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 5, 2024 | 8-K | Current Report |